Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order to provide guidance on the identification of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E., Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280290/
https://www.ncbi.nlm.nih.gov/pubmed/32550266
http://dx.doi.org/10.1038/s41523-020-0168-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280290/
https://www.ncbi.nlm.nih.gov/pubmed/32550266
http://dx.doi.org/10.1038/s41523-020-0168-9

Ejemplares similares